Kymera Therapeutics KYMR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's return on equity?
- Kymera Therapeutics (KYMR) reported return on equity of -27.1% in Q1 2026.
- How has Kymera Therapeutics's return on equity changed year-over-year?
- Kymera Therapeutics's return on equity increased by 15.8% year-over-year, from -32.2% to -27.1%.
- What is the long-term trend for Kymera Therapeutics's return on equity?
- Over 4 years (2021 to 2025), Kymera Therapeutics's return on equity has grown at a -1.1% compound annual growth rate (CAGR), from -27% to -25.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.